薬物乱用検査の世界市場 - 2025年～2033年

薬物乱用検査の世界市場は、2023年に72億6,000万米ドルに達し、2033年には123億1,000万米ドルに達し、予測期間2025年～2033年にはCAGR 5.3％で成長すると予測されています。

薬物乱用検査は、人の体内にある処方薬を検出し、安全性、コンプライアンス、医療評価を確保するための重要なプロセスです。職場のスクリーニング、法医学的調査、スポーツのアンチドーピングの取り組み、臨床診断で使用されます。尿、血液、毛髪、唾液、汗などの生体サンプルを用いて、オピオイド、アンフェタミン、カンナビノイド、コカイン、ベンゾジアゼピンなどの物質を特定します。薬物乱用の増加により、予防、介入、公衆衛生のための薬物検査の重要性が高まっています。

市場力学：

促進要因と抑制要因

薬物乱用障害の有病率の上昇

世界の薬物乱用検査市場は、薬物乱用障害の有病率の増加により活況を呈しています。政府、ヘルスケア機関、雇用主は、依存症の問題を特定し、対処するための強固なプロトコルを導入しています。未治療の薬物乱用がもたらす医療費、職場の生産性低下、法的影響などの社会的・経済的コストは、検査普及の緊急性を高めています。高度で信頼性の高い薬物検査技術への需要が加速し、検査方法の革新が進み、市場が拡大しています。このことは、世界の薬物危機の緩和と公衆衛生の向上における薬物乱用検査の重要な役割を浮き彫りにしています。

例えば、米国薬物乱用・健康調査によると、12歳以上の米国人の16.7%が物質使用障害を持っており、10.2%がアルコール乱用障害を持っていました。約9.7％が薬物使用障害で、2.7％が両方でした。さらに、成人の7.9%は、過去1年間に精神衛生障害と薬物使用障害の両方、または併発障害を患っていました。

高度な薬物検査機器の高コスト

世界の薬物乱用検査市場は、特に低所得地域や小規模組織において、高度な薬物検査機器の高コストによる課題に直面しています。GC-MSシステムやHPLC分析装置には多額の初期投資と継続的なメンテナンスが必要であるため、多くの潜在的ユーザーには手が届きにくいです。この経済的障壁は包括的な検査法の採用を制限し、資金不足のヘルスケア環境における信頼性の高い薬物乱用検査を低下させることで市場の成長可能性を阻害しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 薬物乱用障害の増加
  • 抑制要因
    • 高度な薬物検査機器の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 製品タイプ別

• 消耗品
  • 試薬
  • アッセイキット
  • キャリブレーターとコントロール
• 装置
  • 免疫測定分析装置
  • クロマトグラフィー機器
  • アルコール検知器
• 迅速検査装置
  • ディップカード
  • テストストリップ
  • カセット

第7章 サンプルタイプ別

• 尿
  • 血
  • 唾液
  • 髪
  • 汗

第8章 エンドユーザー別

• 病院
• 診断検査室
• 法医学研究所
• 家庭での検査

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Siemens Healthcare
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Abbott Laboratories
• Thermo Fisher Scientific Inc
• LifeSign LLC
• MP Biomedicals
• Premier Biotech, Inc
• MEDACX Ltd
• Chromsystems Instruments & Chemicals GmbH
• AccuBioTech Co.Ltd
• Screen Italia Srl

第12章 付録

The global drug abuse testing market reached US$ 7.26 billion in 2023 and is expected to reach US$ 12.31 billion by 2033, growing at a CAGR of 5.3% during the forecast period 2025-2033.

Drug abuse testing is a crucial process for detecting prescription drugs in a person's system, ensuring safety, compliance, and medical evaluation. It is used in workplace screening, forensic investigations, sports anti-doping initiatives, and clinical diagnostics. Using biological samples like urine, blood, hair, saliva, or sweat, it identifies substances like opioids, amphetamines, cannabinoids, cocaine, and benzodiazepines. The increasing prevalence of substance abuse has increased the importance of drug testing for prevention, intervention, and public health.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Substance Abuse Disorders

The global drug abuse testing market is booming due to the increasing prevalence of substance abuse disorders. Governments, healthcare institutions, and employers are implementing robust protocols to identify and address addiction issues. The societal and economic costs of untreated drug abuse, including healthcare expenses, workplace productivity loss, and legal repercussions, have heightened the urgency for widespread testing. The demand for advanced and reliable drug testing technologies has accelerated, leading to innovations in testing methods and expanding the market. This highlights the critical role of drug abuse testing in mitigating the global drug crisis and enhancing public health.

For instance, according to US National Survey on Drug Use and Health 2023 revealed that 16.7% of Americans aged 12 and older had a substance use disorder, while 10.2% had an alcohol use disorder. About 9.7% had a drug use disorder, and 2.7% had both. Additionally, 7.9% of adults had both a mental health disorder and a substance use disorder or co-occurring disorders in the past year.

High Cost of Advanced Drug Testing Equipment

The global drug abuse testing market faces challenges due to the high cost of advanced drug testing equipment, particularly in low-income regions and smaller organizations. GC-MS systems and HPLC analyzers require substantial initial investments and ongoing maintenance, making them less affordable for many potential users. This financial barrier restricts the adoption of comprehensive testing methods and hampers the market's growth potential by reducing reliable drug abuse testing in underfunded healthcare settings.

Segment Analysis

The global drug abuse testing market is segmented based on product type, sample type, end user and region.

Product Type:

Consumables segment is expected to dominate the Drug Abuse Testing market share

The consumables segment holds a major portion of the drug abuse testing market share and is expected to continue to hold a significant portion of the drug abuse testing market share during the forecast period.

Consumables are essential in the global drug abuse testing market, ensuring efficient execution of drug testing procedures. They include test kits, reagents, and sample collection devices, used in various settings like hospitals, clinics, laboratories, workplaces, and at-homes. The high demand for consumables is driven by their recurring use in drug testing and continuous innovation in test kits. As drug abuse testing becomes more widespread, consumption of these essential products increases, making consumables a significant revenue generator. Their role in enhancing efficiency, accuracy, and convenience of drug testing solidifies their importance in the global market.

For instance, in June 2024, FUJIFILM Wako Pure Chemicals Corporation has launched two new tests: LumiMAT Pyrogen Detection Kit (LumiMAT), a next-generation monocyte activation test for in vitro2 pyrogen testing, and PYROSTAR Neo+, a recombinant protein reagent for detecting bacterial endotoxins.

End User:

Hospitals segment is the fastest-growing segment in Drug Abuse Testing market share

The hospitals segment is the fastest-growing segment in the drug abuse testing market share and is expected to hold the market share over the forecast period.

Hospitals are key players in the global drug abuse testing market, providing comprehensive drug testing and treatment. Equipped with advanced diagnostic technologies and trained professionals, they conduct a wide range of tests, from initial screenings to confirmatory tests. They also offer medical interventions for substance abuse issues, including counseling, detoxification, and long-term treatment plans. Hospitals' ability to handle complex cases ensures reliable, accurate, and timely drug testing. Their widespread reach and medical expertise expand the adoption of drug abuse testing in clinical and emergency settings. Hospitals often collaborate with public health organizations, law enforcement, and employers to implement large-scale testing programs, driving demand for drug testing services and consumables.

Geographical Analysis

North America is expected to hold a significant position in the Drug Abuse Testing market share

North America holds a substantial position in the drug abuse testing market and is expected to hold most of the market share due to rising awareness of health risks linked to drug abuse and the need for testing in healthcare, workplace, and law enforcement sectors. The prevalence of substance abuse disorders and high adoption of drug testing technologies in hospitals, clinics, and laboratories contribute to market growth. North America's advanced healthcare infrastructure and well-established systems make it a key player in the market, with significant investments in research, development, and innovation of drug testing products and services.

For instance, in August 2024, Psychemedics Corporation, a global leader in hair testing, has launched a new ketamine hair testing solution, a significant advancement in drug-free workplace detection and prevention.

Moreover, in December 2023, Quest Diagnostics has launched a confirmatory testing service for novel psychoactive substances (NPS), covering 88 compounds across various drug classes. The panel aims to help healthcare providers detect potential drug misuse in patients prescribed controlled medications, such as opioids, amid the proliferation of synthetic or "designer" drugs in the US drug supply. Two of these classes, xylazine and acetyl fentanyl, are accelerating America's overdose crisis.

Europe is growing at the fastest pace in the Drug Abuse Testing market

Europe holds the fastest pace in the drug abuse testing market and is expected to hold most of the market share due to the government initiatives, stricter regulations, and a rise in drug treatment programs. The region's strong healthcare infrastructure and public health campaigns contribute to the demand for accurate testing solutions. Additionally, European countries are investing in research to develop more efficient drug testing solutions, further supporting the market's growth. The demand for accurate and reliable testing solutions is fuelled by the region's strong healthcare infrastructure.

For instance, in August 2023, the Office for Life Sciences, UK has allocated USD 6.24 Billion towards the development of new technologies that modernize testing services. Government efforts also include reducing the rates of deaths and overdoses that result from addictive substances, thus increasing the demand for drug testing solutions.

Competitive Landscape

The major global players in the drug abuse testing market include Siemens Healthcare, Abbott, Thermo Fisher Scientific Inc., LifeSign LLC., MP Biomedicals, Premier Biotech, Inc., MEDACX Ltd, Chromsystems Instruments & Chemicals GmbH, AccuBioTech Co.Ltd., Screen Italia Srl, Paramedical s.r.l among others.

Key Developments

• In February 2024, Veriteque USA has partnered with OraSure Technologies to distribute SwabTek surface test kits, a single-use, dry reagent test for narcotics and explosives, alongside its oral fluid drug screening products. This partnership expands OraSure's drug testing portfolio and provides comprehensive solutions for businesses, educators, and security professionals.
• In October 2023, Kerala police have introduced a rapid drug screening system called the SoToxa Mobile Test System, which uses saliva samples and provides results in five minutes. The system is currently being trialed in Thiruvananthapuram city and may be expanded to other parts of the state.

Emerging Players

The emerging players in the drug abuse testing market include American Screening Corporation, Inc., Confirm BioSciences, Phamatech, Inc and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global drug abuse testing market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Sample Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Sample Type
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Substance Abuse Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Advanced Drug Testing Equipment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Consumables*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Reagents
  • 6.2.4. Assay Kits
  • 6.2.5. Calibrators and Controls
• 6.3. Equipment
  • 6.3.1. Immunoassay Analyzers
  • 6.3.2. Chromatography Instruments
  • 6.3.3. Breathalyzers
• 6.4. Rapid Testing Devices
  • 6.4.1. Dip Cards
  • 6.4.2. Test Strips
  • 6.4.3. Cassettes

7. By Sample Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 7.1.2. Market Attractiveness Index, By Sample Type
• 7.2. Urine*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Blood
  • 7.2.4. Saliva
  • 7.2.5. Hair
  • 7.2.6. Sweat

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Diagnostic Laboratories
• 8.4. Forensic Labs
• 8.5. Home Testing

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Siemens Healthcare*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Abbott Laboratories
• 11.3. Thermo Fisher Scientific Inc
• 11.4. LifeSign LLC
• 11.5. MP Biomedicals
• 11.6. Premier Biotech, Inc
• 11.7. MEDACX Ltd
• 11.8. Chromsystems Instruments & Chemicals GmbH
• 11.9. AccuBioTech Co.Ltd
• 11.10. Screen Italia Srl

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1 About Us and Services
• 12.2 Contact Us